Next Article in Journal
Potential Use of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for siRNA
Next Article in Special Issue
Selecting Molecular Recognition. What Can Existing Aptamers Tell Us about Their Inherent Recognition Capabilities and Modes of Interaction?
Previous Article in Journal
New Strategies to Develop Novel Pain Therapies: Addressing Thermoreceptors from Different Points of View
Previous Article in Special Issue
Coupling Aptamers to Short Interfering RNAs as Therapeutics
Pharmaceuticals 2012, 5(1), 49-60; doi:10.3390/ph5010049
Article

Anti-HCV RNA Aptamers Targeting the Genomic cis-Acting Replication Element

,
,
,
 and *
Received: 28 November 2011; in revised form: 15 December 2011 / Accepted: 22 December 2011 / Published: 28 December 2011
(This article belongs to the Special Issue Aptamer-Based Therapeutics)
View Full-Text   |   Download PDF [456 KB, uploaded 28 December 2011]   |   Browse Figures
Abstract: Hepatitis C virus (HCV) replication is dependent on the existence of several highly conserved functional genomic RNA domains. The cis-acting replication element (CRE), located within the 3' end of the NS5B coding region of the HCV genome, has been shown essential for efficient viral replication. Its sequence and structural features determine its involvement in functional interactions with viral RNA-dependent RNA polymerase and distant RNA domains of the viral genome. This work reports the use of an in vitro selection strategy to select aptamer RNA molecules against the complete HCV-CRE. After six selection cycles, five potential target sites were identified within this domain. Inhibition assays using a sample of representative aptamers showed that the selected RNAs significantly inhibit the replication (>80%) of a subgenomic HCV replicon in Huh-7 cell cultures. These results highlight the potential of aptamer RNA molecules as therapeutic antiviral agents.
Keywords: aptamer selection; SELEX; RNA aptamers; anti-HCV aptamers; aptamer therapeutics aptamer selection; SELEX; RNA aptamers; anti-HCV aptamers; aptamer therapeutics
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Marton, S.; Berzal-Herranz, B.; Garmendia, E.; Cueto, F.J.; Berzal-Herranz, A. Anti-HCV RNA Aptamers Targeting the Genomic cis-Acting Replication Element. Pharmaceuticals 2012, 5, 49-60.

AMA Style

Marton S, Berzal-Herranz B, Garmendia E, Cueto FJ, Berzal-Herranz A. Anti-HCV RNA Aptamers Targeting the Genomic cis-Acting Replication Element. Pharmaceuticals. 2012; 5(1):49-60.

Chicago/Turabian Style

Marton, Soledad; Berzal-Herranz, Beatriz; Garmendia, Eva; Cueto, Francisco J.; Berzal-Herranz, Alfredo. 2012. "Anti-HCV RNA Aptamers Targeting the Genomic cis-Acting Replication Element." Pharmaceuticals 5, no. 1: 49-60.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert